Tanda Stephan B. Tanda, a direct shareholder serving as President and CEO, reported a sale of common stock on 2026-08-03. The shares were sold at a weighted average price of $136.1647 per share (range $136.00–$136.52). The total sale amounted to $1,339,588. Following the transaction, Tanda directly…
Tlili Hedi, an officer serving as Segment President, sold 8,854 shares of common stock at $135.00 per share on 2026-08-03. The total sale amount was $1,195,290. Following the transaction, Tlili Hedi directly owns 15,379 shares of common stock.This is an AI-powered summary. It may contain inaccuraci…
Q2 2026 saw record sales and adjusted EPS above guidance, led by strong pharma demand in injectables and consumer healthcare, while beauty and closures improved sequentially. Emergency medicine headwinds are expected to ease, with gross margins set to recover in H2.Based on AptarGroup, Inc. [ATR] Q…
Q2 2026 saw 6% sales growth and revenue gains across all segments, though margins declined due to product mix and operational factors. Adjusted EPS fell 15% year-over-year, but strong demand in Pharma and Closures and ongoing innovation support a positive outlook for Q3.Original document: AptarGrou…
Record quarterly sales surpassed $1 billion, with all segments growing and Pharma leading. Margins declined due to product mix and operational factors, but strong demand and innovation support a positive outlook. Q3 adjusted EPS is guided at $1.45–$1.53.Original document: AptarGroup, Inc. [ATR] SEC…
Aptargroup reported second-quarter 2026 results with revenue topping $1.03 billion, marking the first quarter above $1 billion and a 6% reported sales increase year-over-year. Reported net income was $88.0 million and diluted earnings per share were $1.36; adjusted diluted earnings per share were…
